CDK4 and glioblastoma: No tumors demonstrated EGFR amplification, MET amplification, CDK4 amplification, MDM2 or MDM4 amplification, PTEN homozygous deletion, or NF1 homozygous deletion that are frequent oncogenic events in conventional IDH-wildtype glioblastomas.